Dr Reddys Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)
Dr Reddys Laboratories Ltd · Outcome · 23 Oct 2026, 10:59 pm
Dr Reddys Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 86,978 (-1.5% YoY | +7.4% QoQ) ■ EBITDA: 17,306 (-13.9% YoY | +101.3% QoQ) ■ EBITDA Margin (%): 19.9 (-287 bps YoY | +928 bps QoQ) ■ PAT: 9,248 (-31.3% YoY | +108.1% QoQ) ■ EPS (INR): 11.1 (-31.4% YoY | +108.1% QoQ) Dr Reddys Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance Global Generics ■ Revenue: 77,965 (-0.3% YoY | +8.2% QoQ) ■ EBIT: 43,833 (-5.6% YoY | +18.1% QoQ) ■ EBIT Margin (%): 56.2 (-313 bps YoY | +472 bps QoQ) Pharmaceutical Services and Active Ingredients ■ Revenue: 10,636 (-11.9% YoY | -0.9% QoQ) ■ EBIT: 984 (-42.3% YoY | +154.9% QoQ) ■ EBIT Margin (%): 9.3 (-487 bps YoY | +565 bps QoQ) Others ■ Revenue: 482 (+368.0% YoY | +149.7% QoQ) ■ EBIT: 391 (+7720.0% YoY | +986.1% QoQ) ■ EBIT Margin (%): 81.1 (+7627 bps YoY | +6247 bps QoQ)
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 14 Nov 2026
- Intimation of Analyst meet · 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 05 Nov 2026
- Allotment of Employee Stock options · 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... · 03 Nov 2026
- Transcript of Earnings call · 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 28 Oct 2026
